AAV Production Technology For Scalable, High-Quality Manufacturing

Efficient production of adeno-associated viral vectors remains central to advancing gene therapy from research into widespread clinical use. Conventional plasmid-based transfection methods often limit yield, introduce variability, and increase production costs, creating challenges for scalability and consistent product quality. Plasmid-free production technologies provide a transformative alternative by eliminating transfection steps and leveraging engineered viral systems to drive higher productivity and cleaner outputs. These approaches can significantly boost yields, increase the proportion of fully formed capsids, and reduce downstream purification demands. With demonstrated scalability from development through large-volume manufacturing, they enable reliable expansion to commercial-scale production while maintaining consistency across batches. Additionally, streamlined supply chains and reduced raw material requirements contribute to lower cost of goods and reduced operational complexity. By improving both efficiency and product quality, these innovations help accelerate timelines, support regulatory readiness, and expand patient access to advanced gene therapies with greater confidence.